Open Access

Overexpression of dihydrofolate reductase is a factor of poor survival in acute lymphoblastic leukemia

  • Authors:
    • Jorge Organista‑Nava
    • Yazmín Gómez‑Gómez
    • Berenice Illades‑Aguiar
    • Ana Bertha Rivera‑Ramírez
    • Mónica Virginia Saavedra‑Herrera
    • Marco Antonio Leyva‑Vázquez
  • View Affiliations

  • Published online on: April 4, 2018     https://doi.org/10.3892/ol.2018.8429
  • Pages: 8405-8411
  • Copyright: © Organista‑Nava et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Abstract. Dihydrofolate reductase (DHFR) has an important function in DNA synthesis and is a target of methotrexate, which is a crucial treatment option for acute lymphoblastic leukemia (ALL). However, the number of studies conducted to date on DHFR expression in childhood ALL is limited. The aim of the present study was to determine whether the expression of DHFR is associated with survival in childhood ALL. The expression of DHFR in 96 children with ALL and 100 control individuals was determined using reverse transcription‑quantitative polymerase chain reaction. The results of the present study demonstrated that the expression of DHFR mRNA in children with ALL was significantly increased (P<0.001), compared with that in the control group. In addition, increased levels of DHFR mRNA were observed in patients with B‑cell lineage, compared with patients with T‑cell lineage ALL (P<0.05). The Kaplan‑Meier estimator analysis revealed that children with ALL who exhibited increased levels of DHFR mRNA had a decreased overall survival time (P<0.05). It was observed that certain patient prognostic features (including age, sex, white blood cell count and high DHFR expression), are associated with poor survival (log‑rank test, P<0.05). Therefore, the results of the present study indicated that DHFR upregulation is a factor for poor survival in ALL.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 15 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Organista‑Nava J, Gómez‑Gómez Y, Illades‑Aguiar B, Rivera‑Ramírez AB, Saavedra‑Herrera MV and Leyva‑Vázquez MA: Overexpression of dihydrofolate reductase is a factor of poor survival in acute lymphoblastic leukemia. Oncol Lett 15: 8405-8411, 2018
APA
Organista‑Nava, J., Gómez‑Gómez, Y., Illades‑Aguiar, B., Rivera‑Ramírez, A.B., Saavedra‑Herrera, M.V., & Leyva‑Vázquez, M.A. (2018). Overexpression of dihydrofolate reductase is a factor of poor survival in acute lymphoblastic leukemia. Oncology Letters, 15, 8405-8411. https://doi.org/10.3892/ol.2018.8429
MLA
Organista‑Nava, J., Gómez‑Gómez, Y., Illades‑Aguiar, B., Rivera‑Ramírez, A. B., Saavedra‑Herrera, M. V., Leyva‑Vázquez, M. A."Overexpression of dihydrofolate reductase is a factor of poor survival in acute lymphoblastic leukemia". Oncology Letters 15.6 (2018): 8405-8411.
Chicago
Organista‑Nava, J., Gómez‑Gómez, Y., Illades‑Aguiar, B., Rivera‑Ramírez, A. B., Saavedra‑Herrera, M. V., Leyva‑Vázquez, M. A."Overexpression of dihydrofolate reductase is a factor of poor survival in acute lymphoblastic leukemia". Oncology Letters 15, no. 6 (2018): 8405-8411. https://doi.org/10.3892/ol.2018.8429